Takeda Pharmaceuticals Acquires Inviragen for $250,000,000
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=7ad94fae-3089-4f39-be9c-2148fe9a3426&Preview=1 - Date
5/8/2013 - Company Name
Inviragen - Mailing Address
1613 Prospect Pkwy. Fort Collins, CO 80525 - Company Description
Inviragen, Inc. is committed to developing safe, effective vaccines to address this need. Inviragen is focused on developing life-saving vaccines to protect against emerging infectious diseases worldwide. - Website
http://www.inviragen.com - Transaction Type
M&A - Transaction Amount
$250,000,000 - Transaction Round
- Proceeds Purposes
- M&A Terms
Takeda America Holdings, Inc., and Inviragen, Inc. have entered into a definitive agreement for Takeda to acquire Inviragen for an upfront payment of US$35 million, and future payments of up to US$215 million linked to the progress of clinical development and achievement of key commercial milestones.
